Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Active:	Yes
Cancer Type:	Colon/Rectal Cancer Pancreatic Cancer Sarcoma Solid Tumor	NCT ID:	NCT03715933
Trial Phases:	Phase I	Protocol IDs:	Ph1 INBRX-109 (primary) NCI-2018-03556
Eligibility:	12 - 85 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Inhibrx, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03715933

Summary

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of
INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human
death receptor 5 (DR5).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.